TerminatedNot Applicable

Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.

France75 participantsStarted 2013-05

Plain-language summary

Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D + and D-25% R + develop CMV. The number of available antiviral drugs is reduced and noticeable side effects (neutropenia, renal toxicity) lead to premature discontinuation of therapy or the use of reduced doses that promote non-response to treatment and the emergence of resistance. In case of neutropenia, there are more an increased risk of secondary rejection due to the reduction of immunosuppressive treatment rendered necessary by the haematological reached. Rational use of these molecules is necessary with essential today as the optimal duration of prophylaxis primary issues and the prophylaxis of recurrences in case of CMV infection reported in.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Renal transplant recipient * Immunized against the Cytomegalovirus Exclusion Criteria: * Not willing to participate, no health insurance * clinical evidence of active viral infection * renal transplant recipient whose treatment includes induction antilymphocyte antibodies

What they're measuring

Predictive values of Cytomegalovirus infection

Timeframe: 1 week

Trial details

NCT IDNCT02064699

SponsorUniversity Hospital, Limoges

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-12-13

View on ClinicalTrials.gov More Renal Transplant Recipient trials